Sign in Subscribe

Clear Street Starts Coverage on Caribou Biosciences with Buy Rating

Clear Street initiates coverage of Caribou Biosciences with a Buy rating and a $13 price target, highlighting strong CAR-T pipeline potential.

Clear Street Starts Coverage on Caribou Biosciences with Buy Rating
"Caribou co-founder Rachel Haurwitz". Credit: Elizabeth D. Herman for STAT
Already have an account? Sign in.